Claims involving alleged physical injuries from a prescription medication are often handled through MDLs because individual medical histories, diagnoses, and damages vary significantly from patient to patient
In studies of semaglutide for overweight/obese patients with type 2 diabetes or prediabetes, clinical trials of oral semaglutide (Rybelsus) found a mean weight loss over 26 weeks of -1.0 kg with dosing at 7 mg/d and -2.6 kg with dosing at 14 mg/d
These products are not intended for human or animal consumption, and no diagnostic, therapeutic, or clinical use is intended or implied
Nanofat, on the other hand, has been micronized and enriched, like platelet-rich plasma, to eliminate living cells and acts more like a biostimulatory matrix to improve skin quality and address sub cutaneous fat loss. For patients taking GLP-1 drugs, autologous fat transfer is Rameshs go-to choice for volume restoration
Health Canada has not approved BPC-157 for medical use, meaning it cannot be legally sold as a drug or therapeutic product
